Life sciences Investors

What are Life sciences investors, and what do they look for?

Life sciences covers a wider field than therapeutics, and investors specialise narrowly within it. Beyond drug development sit the tools, instruments, reagents, laboratory software, contract research organisations and manufacturing services that everyone else depends on. Those businesses have revenue, customers and margins that behave like industrial or software companies rather than like clinical programmes, and they are assessed accordingly. For tools and instrument companies, investors examine the installed base and the consumables attached to it. Selling an instrument once produces a support obligation; selling an instrument that requires proprietary consumables produces recurring revenue for its operating life. The ratio between the two determines how the business is valued. For services businesses, capacity utilisation and customer concentration dominate. Contract research and manufacturing operations have high fixed costs, and the difference between full and partial utilisation is the difference between profit and loss. Third, across the whole field, investors assess whether the customer's own funding environment is stable, since much of this sector sells into biotech companies and academic laboratories whose spending tracks capital markets and research budgets.

Why Life sciences is attracting investor interest

Tools and services proved the more reliable business than discovery, and capital has moved accordingly. Selling to everyone attempting drug development avoids the binary outcomes of any single programme, and investors who watched clinical failures wipe out therapeutic positions found the picks-and-shovels layer considerably more predictable. European strength here is genuine and underappreciated. The continent has deep capability in scientific instrumentation, precision manufacturing, reagents and laboratory automation, built on engineering traditions that transfer directly, and several of the world's significant suppliers are European. Manufacturing capacity became strategically important. Dependence on concentrated sources for active ingredients and biological production was identified as a vulnerability, and European policy has directed support towards domestic capacity, which benefits contract manufacturers and the equipment suppliers serving them. Automation demand grew as laboratory labour became scarce and expensive, and as reproducibility concerns pushed research towards standardised, instrumented workflows rather than manual ones. The constraint investors weigh is customer funding. When biotech financing contracts, tools and services companies feel it within quarters, and that cyclicality is a genuine feature of the sector rather than an occasional disruption.

Which funding stages Life sciences investors are active at

Stage patterns follow the business model rather than the science. Tools and instrument companies raise on conventional hardware patterns, with seed funding development, Series A requiring shipped units and early consumable revenue, and later rounds funding manufacturing scale and commercial expansion. Revenue arrives considerably earlier than in therapeutics, which makes these rounds easier to assemble. Laboratory software follows enterprise software stages, selling into research organisations with procurement processes closer to academia or pharmaceutical enterprise depending on the customer. Services businesses, including contract research and manufacturing, are frequently financed with debt and infrastructure capital alongside equity, since facilities and equipment are the dominant cost and utilisation-backed revenue supports lending. Across all three, corporate investors from pharmaceutical and instrument companies are active at every stage, and trade sale to a larger supplier is the most common outcome rather than independent scaling. European public funding for research infrastructure and biomanufacturing capacity is substantial and suits the capital-intensive end of the sector considerably better than it suits the software layer.

Typical check and round sizes in Life sciences

Averages across life sciences would blend an instrument manufacturer, a software company and a contract manufacturing facility, whose capital requirements differ by orders of magnitude. For instrument companies, the structural point is that revenue arrives in two forms. The instrument sale funds the business early; the consumable stream determines its long-term value. Rounds should be sized to reach an installed base large enough that consumable revenue becomes meaningful, since that is the inflection investors underwrite. Manufacturing and certification costs are substantial for anything used in regulated research or clinical settings, and they recur with product revisions. For services businesses, facility capital dominates and should be financed with debt or infrastructure capital rather than equity. Investors expect that structure and treat founders who propose funding a facility from an equity round as unfamiliar with how the sector operates. Working capital matters for anything physical, since instruments and reagents must be manufactured ahead of sale and laboratory customers frequently pay slowly. European public funding for research infrastructure and biomanufacturing capacity is significant and specifically intended for this capital intensity. For comparables, use recent European rounds from companies with the same revenue model.

Types of investors active in Life sciences

What Life sciences investors look for in diligence

Life sciences diligence follows the revenue model rather than the science. For instrument companies, installed base is examined in detail: units shipped, where they are, utilisation, service obligations and consumable attachment rate. Investors want to know what proportion of customers buy consumables at the expected rate, since that assumption underpins the valuation. Manufacturing capability is assessed, covering whether production is in-house or contracted, quality systems appropriate to research or clinical use, and supply chain concentration for critical components. For services businesses, utilisation is the central figure, examined by facility and over time, alongside customer concentration and contract duration. Investors model what happens when a major client's programme ends. Customer funding exposure is analysed explicitly, since selling into biotech companies means revenue tracks their ability to raise. Investors examine what proportion of customers are venture-funded and what happened to orders during the last financing contraction. Regulatory position is verified for anything used in clinical settings, since research use and clinical use carry different requirements. Intellectual property is reviewed for instruments and reagents, where patent protection and freedom to operate matter as they do in any hardware field.

How to build a fundraising strategy as a Life sciences startup

Present the consumable attachment rate rather than instrument sales alone. Investors value the recurring stream far more highly than the hardware revenue, and demonstrating that customers buy consumables at the assumed rate is the most important evidence a tools company can offer. Finance facilities with debt or infrastructure capital rather than equity. Laboratory and manufacturing space is exactly what asset-based lenders exist to fund, and using equity for it dilutes founders unnecessarily. Diversify customer funding exposure where possible. Companies selling exclusively to venture-funded biotech feel every financing contraction directly, and adding pharmaceutical, academic or industrial customers materially reduces the volatility investors price. Pursue European research infrastructure funding, which is substantial for equipment and facilities and specifically designed for capital intensity that private investors avoid. Engage instrument and pharmaceutical strategics early, since they are the realistic acquirers and their distribution reaches laboratories that a young company cannot access directly. Be clear about which sub-sector you occupy in the first sentence, since life sciences investors specialise narrowly and a company describing itself only as life sciences will reach the wrong audience repeatedly.

Common mistakes founders make raising Life sciences capital

Presenting instrument sales without consumable attachment overstates the durability of the revenue, and investors calculate the difference themselves. Funding laboratory or manufacturing facilities from equity is an expensive structural error in a sector where asset-based financing is readily available against exactly those assets. Ignoring customer funding cyclicality leaves companies surprised when a biotech financing contraction reduces orders within a quarter, which has happened repeatedly and is entirely foreseeable. Underestimating the difference between research use and clinical use produces products that cannot be sold into the higher-value market without regulatory work that was never planned. Concentrating revenue in a small number of large customers is common in services businesses and materially risky, since a single programme ending removes a substantial share of utilisation. Describing the company as life sciences without specifying the sub-sector reaches investors who fund therapeutics and will not fund instruments, or the reverse, and wastes a great many meetings.

How Life sciences investment differs across Europe

Germany has exceptional strength in scientific instrumentation and precision manufacturing, with established suppliers and an engineering base that supports new entrants in laboratory equipment and automation. Switzerland combines instrument manufacturing capability with proximity to a dense pharmaceutical industry, making it strong for both tools development and access to customers who buy at scale. The UK has substantial research infrastructure, a large academic customer base and a developed contract research sector, alongside the deepest life science investor community in Europe. The Nordics have strong laboratory automation and diagnostics manufacturing, supported by engineering traditions and close industry links to research institutions. The Netherlands and Belgium host concentrated biotechnology clusters with associated services and manufacturing capacity, and are frequently chosen as European bases for regulatory and logistical reasons. Ireland has significant pharmaceutical and biologics manufacturing capacity built around international companies, which matters for contract manufacturing and supply relationships more than for early research tools. Across the continent, the shared pattern is genuine depth in instrumentation, reagents and manufacturing services, which is the part of life sciences where Europe competes globally without the late-stage capital constraint that affects therapeutics.